Acquired Path AI for $1 billion as part of a shift toward 'Hard Tech' and physical world problem solving.

Engaged in a major collaboration with NVIDIA, committing significant investment to leverage AI in healthcare.

Acquiring massive GPU clusters to accelerate drug discovery through AI factories.

Positioned as a dominant, stable, blue-chip industry leader that actively acquires innovative smaller companies, making it a conservative investment for exposure to growth in diagnostics and personalized medicine.

Announced it would invest $50 billion in the U.S., suggesting the company has the financial strength to adapt to new trade policies and secure its market position.